본문 바로가기
KERD
논문KCI 등재

Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion

천성민|최창민|지원준|이재철|김연주
대한암학회 (Korean Cancer Association)|2022.10|Cancer Research and Treatment|제54권 제4호|pp. 985-995|DOI 10.4143/crt.2021.857

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Non-small cell lung carcinomaT790MOsimertinibLiquid biopsies
주제분류의학일반

초록

Purpose: This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF) or bronchial washing fluid (BWF), and pleural effusion. Materials and methods: Among patients benefited from previous EGFR‒tyrosine kinase inhibitor treatment followed by treatment failure, patients in whom T790M mutations are detected in at least one of the samples including tumor tissues, BALF/BWF, plasma, and pleural effusion were enrolled. T790M mutation was detected by extracting cell free DNA from liquid biopsy samples, using PANA Mutyper. Objective response rate (ORR) and progression-free survival (PFS) with osimertinib treatment were evaluated. Results: Between January 2018 and December 2019, 63 patients were enrolled and received osimertinib. Mean age was 63 years, and 38 (60.3%) were female. Twenty-six patients had T790M mutation in both liquid and tissue samples (group A), 19 patients had only in tissue biopsy samples (group B), and 18 patients had T790M mutation only in liquid biopsy samples (group C). ORR in overall population was 63.5%, and was 61.5% in group A, 68.4% in group B, and 61.1% in group C, respectively. Median PFS in overall patients was 15.6 months (95% confidence interval, 10.7 to 24.2). There was no significant difference in ORR or PFS between groups. Conclusion: Osimertinib showed favorable efficacy in lung cancer patients with acquired resistance to prior EGFR-TKI therapies, who screened positive for harboring T790M mutation detected from cell free DNA extracted from plasma, BALF/BWF, and pleural effusion.

Abstract

Purpose: This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF) or bronchial washing fluid (BWF), and pleural effusion. Materials and methods: Among patients benefited from previous EGFR‒tyrosine kinase inhibitor treatment followed by treatment failure, patients in whom T790M mutations are detected in at least one of the samples including tumor tissues, BALF/BWF, plasma, and pleural effusion were enrolled. T790M mutation was detected by extracting cell free DNA from liquid biopsy samples, using PANA Mutyper. Objective response rate (ORR) and progression-free survival (PFS) with osimertinib treatment were evaluated. Results: Between January 2018 and December 2019, 63 patients were enrolled and received osimertinib. Mean age was 63 years, and 38 (60.3%) were female. Twenty-six patients had T790M mutation in both liquid and tissue samples (group A), 19 patients had only in tissue biopsy samples (group B), and 18 patients had T790M mutation only in liquid biopsy samples (group C). ORR in overall population was 63.5%, and was 61.5% in group A, 68.4% in group B, and 61.1% in group C, respectively. Median PFS in overall patients was 15.6 months (95% confidence interval, 10.7 to 24.2). There was no significant difference in ORR or PFS between groups. Conclusion: Osimertinib showed favorable efficacy in lung cancer patients with acquired resistance to prior EGFR-TKI therapies, who screened positive for harboring T790M mutation detected from cell free DNA extracted from plasma, BALF/BWF, and pleural effusion.

참고문헌 (31)

  1. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
  2. Rosell R, "Screening for epidermal growth factor receptor mutations in lung cancer", N Engl J Med, 361, pp.958~967 (2009)
  3. Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
  4. Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
  5. "FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations" (2018)[URL]
  6. "List of reimbursable drugs" (2018)[URL]
  7. Zappa C, "Non-small cell lung cancer : current treatment and future advances", Transl Lung Cancer Res, 5, pp.288~300 (2016)
  8. Denis MG, "Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC : French subset analysis of the ASSESS study", J Thorac Dis, 11, pp.1370~1378 (2019)
  9. Qiu M, "Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer : a meta-analysis", Cancer Epidemiol Biomarkers Prev, 24, pp.206~212 (2015)
  10. Ryu JS, "Feasibility of bronchial washing fluid-based approach to early-stage lung cancer diagnosis", Oncologist, 24, pp.e603~e606 (2019)
  11. Lee SH, "Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer", Respir Res, 21, pp.142~ (2020)
  12. Rantakokko-Jalava K, "Optimal DNA isolation method for detection of bacteria in clinical specimens by broad-range PCR", J Clin Microbiol, 40, pp.4211~4217 (2002)
  13. Han HS, "Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity", J Thorac Oncol, 7, pp.355~364 (2012)
  14. Janne PA, "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer", N Engl J Med, 372, pp.1689~1699 (2015)
  15. Chouaid C, "Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer : a prospective multicenter study in a real-world setting(GFPC study 12-01)", Lung Cancer, 86, pp.170~173 (2014)
  16. Nosaki K, "Re-biopsy status among non-small cell lung cancer patients in Japan : a retrospective study", Lung Cancer, 101, pp.1~8 (2016)
  17. Kawamura T, "Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure", Cancer Sci, 107, pp.1001~1005 (2016)
  18. Molina-Vila MA, "Liquid biopsy in lung cancer : present and future", Transl Lung Cancer Res, 5, pp.452~454 (2016)
  19. Jenkins S, "Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer", J Thorac Oncol, 12, pp.1061~1070 (2017)
  20. Karlovich C, "Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib(CO-1686)", Clin Cancer Res, 22, pp.2386~2395 (2016)
  21. Oxnard GR, "Association between plasma genotyping and outcomes of treatment with osimertinib(AZD9291)in advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.3375~3382 (2016)
  22. Sacher AG, "Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer", JAMA Oncol, 2, pp.1014~1022 (2016)
  23. Helman E, "Cell-free DNA next-generation sequencing prediction of response and resistance to third-generation EGFR inhibitor", Clin Lung Cancer, 19, pp.518~530 (2018)
  24. Papadimitrakopoulou VA, "Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial : Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer", Cancer, 126, pp.373~380 (2020)
  25. 박철규, "A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2", Cancer Research and Treatment, 51(2), pp.777~787 (2019), 대한암학회
  26. Poletti V, "Bronchoalveolar lavage in malignancy", Semin Respir Crit Care Med, 28, pp.534~545 (2007)
  27. Park S, "Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid", Clin Chem Lab Med, 55, pp.1489~1495 (2017)
  28. Hur JY, "Extracellular vesicle-based EGFR genotyping in bronchoalveolar lavage fluid from treatment-naive non-small cell lung cancer patients", Transl Lung Cancer Res, 8, pp.1051~1060 (2019)
  29. Kiura K, "Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples", Cancer Sci, 109, pp.1177~1184 (2018)
  30. Lee JS, "Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients : a comparison between cell-free DNA and extracellular vesicle-derived DNA", BMC Cancer, 18, pp.1236~ (2018)
  31. Yang JC, "Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer : AURA study phase II extension component", J Clin Oncol, 35, pp.1288~1296 (2017)

관련 논문AI추천

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2김영철, 박철규, 오인재, 조현주, 최유덕대한암학회 · Cancer Research and Treatment2019 · 제51권 제2호A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1김영철, 박철규, 오인재, 조현주, 최유덕대한암학회 · Cancer Research and Treatment2021 · 제53권 제1호Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer김지형, 김혜련, 안병철, 조병철, 허수진, 홍민희연세대학교의과대학 · Yonsei Medical Journal2019 · 제60권 제6호Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib TreatmentGee-Chen Chang, Jeng-Sen Tseng, Kang-Yi Su, Kun-Chieh Chen, Kuo-Hsuan Hsu, Sung-Liang Yu, Tsung-Ying Yang, Yen-Hsiang Huang대한암학회 · Cancer Research and Treatment2018 · 제50권 제4호Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer강혜선, 김승준, 김은영, 박동원, 박찬권, 박철규, 양세훈, 여창동, 윤성훈, 이계영, 이민기, 이상훈, 이승룡, 이승현, 이신엽, 이장호, 이재철, 이정은, 임준혁, 장승훈, 장태원, 최창민대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer김희경, 박근칠, 박웅양, 선종무, 심준호, 안명주, 안진석, 이세훈, 이지윤대한암학회 · Cancer Research and Treatment2019 · 제51권 제1호

이 간행물의 다른 논문 (30건)

Treating Oligometastses, Prelude or Just Hassles of Systemic Treatment이대호pp. 951-952Role of Local Treatment for Oligometastasis: A Comparability Based Meta-Analysis김경환, 임채홍, 조원경, 이종훈, 안용찬, 김영석, 지의규, 서양권pp. 953-969Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional StudyAnikó Bozsik, János Papp, Vince Kornél Grolmusz, Attila Patócs, Edit Oláh, Henriett Butzpp. 970-984The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non‒Small Cell Lung Cancer정원기, 김진흠, 최혜미, 채금주pp. 996-1004A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer김동하, 최창민, 고대현, 김상엽, 김용만, 지원준, 최명근, 김어진, 정재섭, 노진경, 이재철, 도은주, 강윤미, 조용희pp. 1005-1016
원문 보기